MedTrace Logo

PTK/ZK in Disseminated Malignant Melanoma

NCT00615160 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-10-06

No results posted yet for this study

Summary

To evaluate the efficacy of PTK-ZK on metastatic melanoma either as a single agent treatment or in combination with standard chemotherapy according to RECIST criteria. Further to evaluate the safety and tolerability of PTK-ZK in patients with metastatic melanoma either as a single agent treatment or in combination with standard chemotherapy

Conditions

Interventions

DRUG

PTK787/ZK 222584

PTK-ZK capsules taken orally with a daily flat dose of 1250 mg

DRUG

Dacarbazine

Dacarbazine 850 mg/m² on day 1 q4w

Sponsors & Collaborators

  • Michael Weichenthal

    lead OTHER

Principal Investigators

  • Michael Weichenthal, MD · UK-SH Department of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00615160 on ClinicalTrials.gov